Published in Pharmacol Res on June 04, 2010
P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal (2012) 1.00
P2 receptors and platelet function. Purinergic Signal (2011) 0.98
Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal (2011) 0.90
Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic beta cells. Biochem Pharmacol (2010) 0.90
Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. Bioconjug Chem (2010) 0.85
The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. Purinergic Signal (2012) 0.85
Blood cells: an historical account of the roles of purinergic signalling. Purinergic Signal (2015) 0.78
Ser352 and Ser354 in the carboxyl terminus of the human P2Y(1) receptor are required for agonist-promoted phosphorylation and internalization in MDCK cells. Br J Pharmacol (2011) 0.78
Virtual screening leads to the discovery of novel non-nucleotide P2Y₁ receptor antagonists. Bioorg Med Chem (2012) 0.77
Ligand binding to a G protein-coupled receptor captured in a mass spectrometer. Sci Adv (2017) 0.75
Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev (2007) 6.05
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev (2006) 5.28
Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem (1998) 2.32
Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol (1996) 2.10
Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol (1998) 1.80
Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol (2006) 1.71
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol (2001) 1.59
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem (2003) 1.57
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol (2002) 1.49
The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood (1998) 1.48
Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther (2004) 1.31
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol (2004) 1.25
Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol (2004) 1.23
Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost (2000) 1.21
Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol (2004) 1.18
Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol (2004) 1.16
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res (2006) 1.08
[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol (2006) 1.07
Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol (2004) 1.07
Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics (2007) 0.98
(N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets. J Thromb Haemost (2006) 0.92
Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. Comb Chem High Throughput Screen (2008) 0.86
Synthesis and binding characteristics of N-(1-naphthyl)-N'-(3-[(125)I]-iodophenyl)-N'-methylguanidine ([(125)I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation. Nucl Med Biol (2000) 0.86
P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. J Thromb Haemost (2006) 0.83
P2Y1 gene polymorphism and ADP-induced platelet response. J Thromb Haemost (2005) 0.81
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev (2006) 5.28
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature (2007) 3.78
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med (2003) 3.71
Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol (2003) 3.47
Platelet-derived serotonin mediates liver regeneration. Science (2006) 2.98
Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc (2008) 2.80
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol (2010) 2.55
Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci (2003) 2.37
Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15
Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem (2004) 2.15
Structure of Galpha(i1) bound to a GDP-selective peptide provides insight into guanine nucleotide exchange. Structure (2005) 1.98
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem (2002) 1.97
PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv (2003) 1.95
RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of Gi family G-proteins with differential selectivity and maximal activity. J Biol Chem (2003) 1.91
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 1.84
N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharmacol (2003) 1.82
Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex. Science (2010) 1.78
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem (2002) 1.77
Structure-based discovery of A2A adenosine receptor ligands. J Med Chem (2010) 1.71
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology (2010) 1.70
Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci (2003) 1.69
DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog (2008) 1.67
Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood (2013) 1.65
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol (2011) 1.64
General and versatile autoinhibition of PLC isozymes. Mol Cell (2008) 1.62
Crystal structure of Rac1 bound to its effector phospholipase C-beta2. Nat Struct Mol Biol (2006) 1.60
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem (2003) 1.57
The UDP-sugar-sensing P2Y(14) receptor promotes Rho-mediated signaling and chemotaxis in human neutrophils. Am J Physiol Cell Physiol (2012) 1.57
Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Intensive Care Med (2013) 1.56
A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med (2003) 1.56
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem (2005) 1.54
Release of cellular UDP-glucose as a potential extracellular signaling molecule. Mol Pharmacol (2003) 1.53
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42. Blood (2013) 1.52
2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol (2002) 1.52
Crystal structure of the multifunctional Gbeta5-RGS9 complex. Nat Struct Mol Biol (2008) 1.52
MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther (2005) 1.51
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol (2002) 1.49
Biogenesis of the demarcation membrane system (DMS) in megakaryocytes. Blood (2013) 1.47
Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol Pharmacol (2003) 1.46
Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. Blood (2012) 1.45
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem (2002) 1.44
Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem (2005) 1.43
Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. JACC Cardiovasc Interv (2010) 1.42
Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation. Development (2006) 1.41
Molecular Architecture of G Protein-Coupled Receptors. Drug Dev Res (1996) 1.39
Direct activation of phospholipase C-epsilon by Rho. J Biol Chem (2003) 1.39
G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci Signal (2012) 1.38
Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. J Med Chem (2009) 1.38
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol (2004) 1.38
Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem (2004) 1.34
Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 1.31
The pleckstrin homology domain of phospholipase C-beta2 as an effector site for Rac. J Biol Chem (2003) 1.31
Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther (2004) 1.31
Conformational changes involved in G-protein-coupled-receptor activation. Trends Pharmacol Sci (2008) 1.29
Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood (2007) 1.29
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem (2006) 1.28
Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol (2002) 1.27
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem (2002) 1.26
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A (2004) 1.25
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2003) 1.25
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol (2004) 1.25
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2006) 1.25
Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. J Biol Chem (2003) 1.24
Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods (2007) 1.24
A unique fold of phospholipase C-beta mediates dimerization and interaction with G alpha q. Nat Struct Biol (2002) 1.23
Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol (2004) 1.23
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nat Commun (2012) 1.22
Keynote review: allosterism in membrane receptors. Drug Discov Today (2006) 1.22
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (2005) 1.21
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol (2009) 1.20
Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J (2012) 1.20
Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol (2005) 1.20
Emerging adenosine receptor agonists. Expert Opin Emerg Drugs (2007) 1.19
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem (2007) 1.18
Mechanism of phosphorylation-induced activation of phospholipase C-gamma isozymes. J Biol Chem (2010) 1.18
Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem Pharmacol (2005) 1.18
Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol (2004) 1.18
Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev (2006) 1.18
Paraffin embedding tissue samples for sectioning. CSH Protoc (2008) 1.18
Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal (2008) 1.17